Polypyrimidine tract-binding proteins are essential for B cell development.

Polypyrimidine tract-binding protein 1 (PTBP1) is a RNA-binding protein (RBP) expressed throughout B cell development. Deletion of Ptbp1 in mouse pro-B cells results in upregulation of PTBP2 and normal B cell development. We show that PTBP2 compensates for PTBP1 in B cell ontogeny as deletion of both Ptbp1 and Ptbp2 results in a complete block at the pro-B cell stage and a lack of mature B cells. In pro-B cells PTBP1 ensures precise synchronisation of the activity of cyclin dependent kinases at distinct stages of the cell cycle, suppresses S-phase entry and promotes progression into mitosis. PTBP1 controls mRNA abundance and alternative splicing of important cell cycle regulators including CYCLIN-D2, c-MYC, p107 and CDC25B. Our results reveal a previously unrecognised mechanism mediated by a RBP that is essential for B cell ontogeny and integrates transcriptional and post-translational determinants of progression through the cell cycle

Essential requirement for polypyrimidine tract binding proteins 1 and 3 in the maturation and maintenance of mature B cells in mice

Abstract: The maturation of immature B cells and the survival of mature B cells is stringently controlled to maintain a diverse repertoire of antibody specificities while avoiding self‐reactivity. At the molecular level this is regulated by signaling from membrane Ig and the BAFF‐receptor that sustain a pro‐survival program of gene expression. Whether and how posttranscriptional mechanisms contribute to B cell maturation and survival remains poorly understood. Here, we show that the polypyrimidine tract binding proteins (PTBP) PTBP1 and PTBP3 bind to a large and overlapping set of transcripts in B cells. Both PTBP1 and PTBP3 bind to introns and exons where they are predicted to regulate alternative splicing. Moreover, they also show high‐density of binding to 3’ untranslated regions suggesting they influence the transcriptome in diverse ways. We show that PTBP1 and PTBP3 are required in B cells beyond the immature cell stage to sustain transitional B cells and the B1, marginal zone and follicular B cell lineages. Therefore, PTBP1 and PTBP3 promote the maturation of quiescent B cells by regulating gene expression at the posttranscriptional level

RNA-binding proteins ZFP36L1 and ZFP36L2 promote cell quiescence.

Progression through the stages of lymphocyte development requires coordination of the cell cycle. Such coordination ensures genomic integrity while cells somatically rearrange their antigen receptor genes [in a process called variable-diversity-joining (VDJ) recombination] and, upon successful rearrangement, expands the pools of progenitor lymphocytes. Here we show that in developing B lymphocytes, the RNA-binding proteins (RBPs) ZFP36L1 and ZFP36L2 are critical for maintaining quiescence before precursor B cell receptor (pre-BCR) expression and for reestablishing quiescence after pre-BCR-induced expansion. These RBPs suppress an evolutionarily conserved posttranscriptional regulon consisting of messenger RNAs whose protein products cooperatively promote transition into the S phase of the cell cycle. This mechanism promotes VDJ recombination and effective selection of cells expressing immunoglobulin-μ at the pre-BCR checkpoint.This work was funded by the Biotechnology and Biological Sciences Research Council, a Medical Research Council CASE studentship with GSK, an MRC centenary award (A.G) and project grants from Bloodwise. DJH was supported by a Medical Research Council Clinician Scientist FellowshipThis is the author accepted manuscript. The final version is available from the American Association for the Advancement of Science via http://dx.doi.org/10.1126/science.aad597

The RNA-binding protein PTBP1 is necessary for B cell selection in germinal centers.

Antibody affinity maturation occurs in germinal centers (GCs), where B cells cycle between the light zone (LZ) and the dark zone. In the LZ, GC B cells bearing immunoglobulins with the highest affinity for antigen receive positive selection signals from helper T cells, which promotes their rapid proliferation. Here we found that the RNA-binding protein PTBP1 was needed for the progression of GC B cells through late S phase of the cell cycle and for affinity maturation. PTBP1 was required for proper expression of the c-MYC-dependent gene program induced in GC B cells receiving T cell help and directly regulated the alternative splicing and abundance of transcripts that are increased during positive selection to promote proliferation

Treatment with tocilizumab or corticosteroids for COVID-19 patients with hyperinflammatory state: a multicentre cohort study (SAM-COVID-19)

Objectives: The objective of this study was to estimate the association between tocilizumab or corticosteroids and the risk of intubation or death in patients with coronavirus disease 19 (COVID-19) with a hyperinflammatory state according to clinical and laboratory parameters. Methods: A cohort study was performed in 60 Spanish hospitals including 778 patients with COVID-19 and clinical and laboratory data indicative of a hyperinflammatory state. Treatment was mainly with tocilizumab, an intermediate-high dose of corticosteroids (IHDC), a pulse dose of corticosteroids (PDC), combination therapy, or no treatment. Primary outcome was intubation or death; follow-up was 21 days. Propensity score-adjusted estimations using Cox regression (logistic regression if needed) were calculated. Propensity scores were used as confounders, matching variables and for the inverse probability of treatment weights (IPTWs). Results: In all, 88, 117, 78 and 151 patients treated with tocilizumab, IHDC, PDC, and combination therapy, respectively, were compared with 344 untreated patients. The primary endpoint occurred in 10 (11.4%), 27 (23.1%), 12 (15.4%), 40 (25.6%) and 69 (21.1%), respectively. The IPTW-based hazard ratios (odds ratio for combination therapy) for the primary endpoint were 0.32 (95%CI 0.22-0.47; p < 0.001) for tocilizumab, 0.82 (0.71-1.30; p 0.82) for IHDC, 0.61 (0.43-0.86; p 0.006) for PDC, and 1.17 (0.86-1.58; p 0.30) for combination therapy. Other applications of the propensity score provided similar results, but were not significant for PDC. Tocilizumab was also associated with lower hazard of death alone in IPTW analysis (0.07; 0.02-0.17; p < 0.001). Conclusions: Tocilizumab might be useful in COVID-19 patients with a hyperinflammatory state and should be prioritized for randomized trials in this situatio

Ratten iNKT Zellen: Phänotyp und Funktion

iNKT cells are a population of T cells with unique characteristics. In contrast to most αβ T cells which recognize peptides presented by highly polymorphic MHC molecules, iNKT cells are reactive to glycolipids presented by CD1d, a non-polymorphic MHC-I like molecule. Moreover, whereas MHC-restricted αβ T cells bear highly variable receptors (TCRs) formed after somatic recombination of the V(D)J gene segments, the TCR of iNKT cells is formed by an invariant α chain, which always contains the same gene segments: AV14 and AJ18; and a β chain of limited BV gene usage: BV8S2, BV7 or BV2, in the mouse. This invariant α chain is the reason for which these cells are named “i” and the NK part of their name refers to the expression of receptors typical of natural killer (NK) cells. iNKT cells recognize glycolipids of endogenous and microbial origin. After activation they secrete large amounts of very different cytokines such as IFN-γ and IL-4 and thus influence immune responses and pathological conditions. One of the most potent iNKT cell agonists, recognized by the semi-invariant TCR, is the synthetic glycolipid α-Galactosylceramide (α-Gal). iNKT cells can be visualized using CD1d-multimeric complexes loaded with α-Gal and flow cytometry, since this reagent has enough avidity to stain these cells. Interestingly, mouse iNKT cells can be stained with human α-Gal-loaded CD1d oligomers and human iNKT cells can also be visualized with mouse α-Gal-loaded CD1d oligomers, indicating a high degree of conservation of the recognition of α-Gal presented by CD1d through evolution. Previous studies showed that rats have the genes necessary to build semi-invariant TCRs: They have a CD1d homologue; one or two BV8S2 homologues and interestingly, up to ten AV14 gene segments, which are highly conserved when compared to the mouse genes. Importantly, it has been shown at least for two of these AV14 gene segments that they can produce invariant TCRα chains which, when coexpressed with BV8-containing β chains, react to α-Gal presented by rat CD1d. Furthermore, ex vivo stimulation of primary splenocytes with α-Gal results in the secretion of IL-4 and IFN-γ. Surprisingly, rat semi-invariant TCRs do not recognize α-Gal presented by mouse CD1d and accordingly, mouse α-Gal-loaded CD1d tetramers failed to stain a discrete population of rat iNKT cells. Taking all together, despite that strong evidence suggested that iNKT cells are present in the rat, the direct identification of such population and the analysis of CD1d-restricted immune responses were still pending for this species. Hence the work presented in this doctoral thesis was aimed to identify iNKT cells, to analyze their phenotype and also to study the distribution and function of CD1d in the rat. For these purposes, we produced essential reagents which were still lacking such as rat specific anti-CD1d monoclonal antibodies and rat CD1d oligomers. Importantly, two of three anti-rat CD1d monoclonal antibodies (all of them generated in our laboratory before this thesis was initiated) also recognized mouse CD1d and therefore allowed a direct comparison of CD1d expression between rat and mouse. Whereas CD1d distribution in the hematopoietic system was found to be extremely similar between these two species; in non-lymphatic tissues important differences were observed. Interestingly, CD1d protein was detected at not yet described sites such as the rat exocrine pancreas and rat and mouse Paneth cells. These monoclonal antibodies did not only allowed the analysis of CD1d expression, but also the first demonstration of the function of rat CD1d as an antigen presenting molecule, since cytokine release in response to α-Gal was blocked when they were added to ex vivo cultures of rat primary cells. Staining of primary rat iNKT cells (possible now with the newly generated rat CD1d oligomers) revealed interesting similarities with human iNKT cells. First, we observed that rat iNKT cells are only a minority among all NKR-P1A/B positive T cells. Human iNKT cells constitute also a very small proportion of NKR-P1A (CD161) expressing T cells, whereas in mice inbred strains which express NKR-P1C (NK1.1), most of NKRP1C expressing T cells are iNKT cells. Second, the majority of rat iNKT cells are either CD4 or DN and only a small proportion expresses CD8β. These findings are similar to humans and different to mice which lack CD8+ iNKT cells. Third, analysis of various inbred rat strains demonstrated different iNKT cell frequencies which correlated with cytokine secretion after α-Gal stimulation of primary cells. In comparison to mice, iNKT cell numbers are markedly reduced in rats. In F344 rats, inbred rat strain which released the highest cytokine amounts after α-Gal stimulation, approximately 0.25% and 0.1% of total liver and spleen lymphocytes, respectively, are iNKT cells. In contrast, in LEW rats iNKT cells were practically absent and neither IL-4 nor IFN-γ were detected after stimulation of primary cells with α-Gal. Once more, these frequencies are very close to those observed in humans. Last, as reported for human peripheral blood cells, rat iNKT cells could be easily expanded in vitro by adding α-Gal to cultures of intrahepatic lymphocytes, whereas the expansion of mouse iNKT cells was not possible using the same protocol. The presence of a multimember AV14 gene segment family in the rat is an intriguing characteristic. These AV14 gene segments are extremely homologous except in the CDR2α region. Based on the amino acid sequence of this region they have been divided into two different types: Type I and II. A specific tissue distribution of the different types was proposed in the first study where the presence of several AV14 gene segments was described. We also analyzed the AV14 gene segment usage in F344 and LEW inbred rat strains. In F344 rats we found no preferential usage of either AV14 gene segment type in the spleen and the liver but type II AV14 gene segments appeared more frequently in the thymus. In contrast, LEW rats show a preferential usage of type I AV14 gene segments in all three compartments analyzed: Thymus, spleen and liver. Taken all together, the usage of newly generated reagents allowed to gain novel insights into CD1d expression in the rat and in the mouse and to directly identify rat iNKT cells for the first time. The phenotypic and functional analysis of rat iNKT cells revealed numerous similarities with human iNKT cells. These are of special interest, since rats serve to investigate several pathological conditions including models for autoimmune diseases. The possibility now to analyze iNKT cells and CD1d-restricted T cell responses in the rat might help to understand the pathogenesis of such diseases. In addition, the uncomplicated in vitro expansion and culture of rat iNKT cells should facilitate the analysis of the immunomoldulatory capacities of these cells.iNKT Zellen sind eine Population von T Zellen mit einigen Besonderheiten. Anders als die meisten αβ T Zellen, deren T Zell Rezeptoren (TZRs) für von hochpolymorphen MHC Molekülen präsentierte Peptide spezifisch sind, erkennen iNKT Zellen Glycolipide die von CD1d, einem nicht polymorphem MHC-I artigen Moleküle, präsentiert werden. Während MHC-restringierte αβ T Zellen sehr unterschiedliche TZRs haben, die nach somatischer Rekombination der V(D)J Gensegmente generiert werden, besteht der TZR der iNKT Zellen aus einer invarianten α Kette und einer β Kette mit einem limitierten BV Gen Repertoire (BV8S2, BV7 und BV2 in Maus). Die invariante α Kette, auf die das i im Namen der iNKT Zellen verweist, enthält in der Maus immer AV14 und AJ18 kodierte V-Regionen. Das NK in ihrem Namen verweist darauf, dass sie häufig NK-Zell typische Oberflächenmoleküle exprimieren. iNKT Zellen erkennen Glycolipide endogenen und mikrobiellen Ursprungs und sezernieren nach Aktivierung große Mengen verschiedener Zytokine wie zum Beispiel IL-4 und IFN-γ. Auf diese Weise beeinflussen sie Immunantwort und pathologische Zustände. Eine der potentesten iNKT-Zell-TZR Agonisten ist das α-Galactosylceramid (α-Gal) und α-Gal beladene CD1d-Multimere ermöglichen es iNKT Zellen zu färben und mittels Durchflusszytometrie sichtbar zu machen. Die hohe Konservierung der iNKT TZR-CD1d Interaktion ermöglicht es sogar, Maus iNKT Zellen mittels α-Gal beladenen humanen CD1d-Multimere zu färben. Vorhergehende Studien zeigten, dass Ratten die notwendigen Gene für die Generierung der semi-invarianten TZR haben: Sie besitzen ein CD1d Homolog, ein oder zwei BV8S2 Homologe und bis zu zehn AV14 Gensegmente, die im Vergleich zu den Maus-AV14 Genen hoch konserviert sind. Mehrere dieser AV14 Gensegmenten wurden mit AJ18 zusammen rearrangiert gefunden und für mindestens zwei dieser invarianten α Ketten wurde gezeigt, dass sie zusammen mit BV8 enthaltenden β Ketten TZR bilden, die von CD1d präsentiertes α-Gal erkennen. Weiterhin wurde gezeigt, dass primäre Ratten- Milzzellen und intrahepatische Lymphozyten nach Kultur mit α-Gal IL-4 und IFN-γ sezernieren. Auf Grund dieser Befunde und der starken Konservierung der CD1d Gene und der Gene, die die semi-invarianten TZR kodieren, überrascht es, dass keine definierte Zellpopulation von intrahepatischen Rattenlymphozyten mittels α-Gal beladenen Maus CD1d-Tetrameren gefärbt wurde. Zusammengefasst kann gesagt werden, dass die direkte Identifizierung der Zellen und die Analyse der CD1d restringierten Immunantworten in der Ratten noch austand, obwohl es starke Hinweise für die Existenz der iNKT Zellen in dieser Art gab. Infolgedessen sind die Ziele dieser Arbeit: die Identifizierung der Ratten iNKT Zellen, die Analyse ihres Phänotyps und die Untersuchung der CD1d-restringierten Immunantworten. Um diese Ziele zu erreichen, wurden noch fehlende essentielle Reagenzien hergestellt, wie die ersten Ratten-CD1d spezifischen monoklonalen Antikörper und Ratten CD1d Oligomere. Zwei der drei charakterisierten monoklonalen Antikörpern erkennen sowohl Ratten CD1d als auch Maus CD1d. Dies ermöglichte den direkten Vergleich der CD1d Expression zwischen beiden Spezies (diese Antikörper wurden in unserem Labor vor dem Anfang dieser Doktorarbeit hergestellt). Während die CD1d Verteilung im hämatopoetischen System beider Arten äußerst ähnlich ist, wurden in nicht lymphatischen Geweben sehr starke Unterschiede gefunden. Interessanterweise wurde das CD1d Protein auch an noch nicht beschriebenen Stellen wie im exokrinen Pankreas der Ratte und in Paneth Zellen von Maus und Ratte beobachtet. Die monoklonalen Antikörper erlaubten nicht nur die Analyse der CD1d Verteilung, sondern auch den Beweis der Funktion von CD1d als Antigen präsentierendes Molekül, weil die Zugabe der Antikörper zu ex vivo Kulturen von primären Zellen die Sekretion von Zytokinen bei der Stimulation mit α-Gal hemmt. Färbungen von primären Ratten iNKT Zellen, jetzt möglich durch die neu generierte Ratten CD1d-Dimere, zeigten interessante Gemeinsamkeiten mit humanen iNKT Zellen. Es wurde erstens beobachtet, dass Ratten iNKT Zellen nur eine Minderheit unter allen NKR-P1A/B positiven T Zellen sind. Dies ähnelt den humanen iNKT Zellen, die ebenfalls auch nur ein sehr kleinen Teil der NKR-P1A (CD161) exprimierenden T Zellen stellen, während in Mausstämmen, die NKR-P1C (NK1.1) exprimieren, die Mehrheit der NKR-P1C positiven T Zellen iNKT Zellen sind. Zweitens sind die meisten Ratten iNKT Zellen CD4 positiv oder doppelt negativ während nur ein kleiner Anteil CD8β exprimiert. Diese Befunde gleichen denen mit humanen iNKTs und unterscheiden sich von Maus iNKTs, die immer CD8β negativ sind. Drittens zeigt die Analyse von verschiedenen Rattenstämmen, ähnlich wie beim Menschen, 10-100 fach geringere Frequenzen von iNKT Zellen als in der Maus. In F344 Ratten sind etwa 0.25% aller Lymphozyten in der Leber und etwa 0.1% aller Milzzellen iNKT Zellen. Wobei dies der Rattenstamm ist, der die größte Mengen an Zytokinen nach α-Gal Stimulation produziert. In LEW Ratten, die keine Zytokine nach α-Gal Stimulation produzierten, konnten iNKT Zellen praktisch nicht gefärbt werden. Schließlich konnten, wie bei humanen peripherischen Blutzellen beobachtet, Ratten iNKT Zellen durch alleinige Zugabe von α-Gal in vitro expandiert werden, während dies mit Maus iNKT Zellen nicht möglich war. Eine faszinierende bislang nur in der Ratte gemachte Beobachtung ist die Existenz einer AV14 Multigenfamilie, deren Mitglieder bis auf die CDR2 kodierende Region hochhomolog sind. Basiert auf der Aminosäuresequenz dieser Region wurde diese Familie in zwei Gruppen aufgeteilt: Typ I und II. Die erste Studie, in der diese zwei verschiedenen Typen beschrieben wurden, schlug eine spezifische Gewebsverteilung von AV14 positiven TCR vor. Wir haben ebenfalls die Benutzung dieser AV14 Gene in F344 und LEW Inzuchtrattenstämmen analysiert und gefunden, dass es in F344 Leber und Milz keine Präferenz für einen bestimmten AV14 Typ gibt. Jedoch wurde der Typ II häufiger in F344 Thymus gefunden. Im Vergleich zeigen LEW Ratten eine bevorzugte Benutzung des Typ I in allen analysierten Geweben (Thymus, Milz und Leber). Zusammengefasst kann gesagt werden, dass diese Studie mit Hilfe neu generierter Reaganzien neue Erkenntnisse zur CD1d Expression in Ratte und Maus gewonnen wurden und erstmals eine direkte phänotypische und funktionelle Analyse von iNKT Zellen der Ratte durchgeführt wurde. Es wurden eine Reihe von Gemeinsamkeiten zwischen iNKT Zellen von Ratte und Mensch gefunden. Diese sind vor allem deshalb von Interesse, da das Versuchstier Ratte für eine Reihe von Autoimmunkrankheiten und andere pathologische Zustände als Modellorganismus dient. Es ist zu erwarten, dass weitere Untersuchungen von CD1d-restringierten Zellen der Ratte neue Einsichten in die Genese dieser Krankheiten ermöglicht. Darüberhinaus sollte die in der Ratte beobachtete einfach durchzuführende in vitro Kultur und Expansion von iNKT Zellen eine Analyse ihrer immunmodulatorischen Eigenschaften deutlich erleichtern

Polypyrimidine tract-binding proteins are essential for B cell development.

Polypyrimidine tract-binding protein 1 (PTBP1) is a RNA-binding protein (RBP) expressed throughout B cell development. Deletion of Ptbp1 in mouse pro-B cells results in upregulation of PTBP2 and normal B cell development. We show that PTBP2 compensates for PTBP1 in B cell ontogeny as deletion of both Ptbp1 and Ptbp2 results in a complete block at the pro-B cell stage and a lack of mature B cells. In pro-B cells PTBP1 ensures precise synchronisation of the activity of cyclin dependent kinases at distinct stages of the cell cycle, suppresses S-phase entry and promotes progression into mitosis. PTBP1 controls mRNA abundance and alternative splicing of important cell cycle regulators including CYCLIN-D2, c-MYC, p107 and CDC25B. Our results reveal a previously unrecognised mechanism mediated by a RBP that is essential for B cell ontogeny and integrates transcriptional and post-translational determinants of progression through the cell cycle

The RNA-binding protein PTBP1 is necessary for B cell selection in germinal centers.

Antibody affinity maturation occurs in germinal centers (GCs), where B cells cycle between the light zone (LZ) and the dark zone. In the LZ, GC B cells bearing immunoglobulins with the highest affinity for antigen receive positive selection signals from helper T cells, which promotes their rapid proliferation. Here we found that the RNA-binding protein PTBP1 was needed for the progression of GC B cells through late S phase of the cell cycle and for affinity maturation. PTBP1 was required for proper expression of the c-MYC-dependent gene program induced in GC B cells receiving T cell help and directly regulated the alternative splicing and abundance of transcripts that are increased during positive selection to promote proliferation

Polypyrimidine tract binding protein 1 regulates the activation of mouse CD8 T cells

Funder: the BBSRC Core Capability Grant to the Babraham InstituteFunder: Cambridge Commonwealth, European and International Trust studentshipAbstract: The RNA‐binding protein polypyrimidine tract binding protein 1 (PTBP1) has been found to have roles in CD4 T‐cell activation, but its function in CD8 T cells remains untested. We show it is dispensable for the development of naïve mouse CD8 T cells, but is necessary for the optimal expansion and production of effector molecules by antigen‐specific CD8 T cells in vivo. PTBP1 has an essential role in regulating the early events following activation of the naïve CD8 T cell leading to IL‐2 and TNF production. It is also required to protect activated CD8 T cells from apoptosis. PTBP1 controls alternative splicing of over 400 genes in naïve CD8 T cells in addition to regulating the abundance of ∼200 mRNAs. PTBP1 is required for the nuclear accumulation of c‐Fos, NFATc2, and NFATc3, but not NFATc1. This selective effect on NFAT proteins correlates with PTBP1‐promoted expression of the shorter Aβ1 isoform and exon 13 skipped Aβ2 isoform of the catalytic A‐subunit of calcineurin phosphatase. These findings reveal a crucial role for PTBP1 in regulating CD8 T‐cell activation